Literature DB >> 29419532

Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis.

Joann V Pinkerton1, Andra H James2.   

Abstract

For women at elevated risk of thrombosis, clinicians are challenged to relieve menopausal symptoms without increasing the risk of thrombosis. Oral menopausal hormone therapy increases the risk of venous thromboembolism by 2-fold to 3-fold. Observational studies suggest less thrombotic risk with transdermal therapies and with progesterone over synthetic progestogens (progestins), but the data are limited. Beneficial nonpharmacologic therapies include cognitive behavioral therapy and clinical hypnosis, whereas beneficial nonhormonal pharmacologic therapies include selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. For treatment of the genitourinary syndrome of menopause, vaginal lubricants and moisturizers, low-dose vaginal estrogen, and intravaginal dehydroepiandrosterone are options.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29419532     DOI: 10.1097/GRF.0000000000000358

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  3 in total

1.  Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.

Authors:  Patricia Loranca-Moreno; Juan Moises Ocampo-Godínez; Alan Rios-Espinosa; Magdalena Cruz-Luna; Carolina Garmendia-Gallardo; Merle Yasmin Hernández-Castañón; Verónica Yazmin Hernández-Hernández; Paula Mariana Sánchez-Tinoco; Alma Bajonero-Domínguez; Jael Adrián Vergara Lope-Núñez; Marco Antonio Álvarez-Pérez; José Luis González-Quiroz
Journal:  Arch Gynecol Obstet       Date:  2022-08-23       Impact factor: 2.493

Review 2.  Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS.

Authors:  Lisa R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2021-04-30       Impact factor: 4.592

Review 3.  Is there a gender effect in polycythemia vera?

Authors:  Francesca Palandri; Barbara Mora; Naseema Gangat; Lucia Catani
Journal:  Ann Hematol       Date:  2020-10-02       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.